Comparison · NCT03584854-0beaed03
15-methyl Prostaglandin F2α vs Methylergonovine Maleate: Number of Subjects Requiring Additional Intervention
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 15-methyl Prostaglandin F2α vs Methylergonovine Maleate: Number of Subjects Requiring Additional Intervention. Trial comparisons, record NCT03584854-0beaed03. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03584854-0beaed03
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.08 | 0.0315 | 0.188 | wilson | |
| Risk in group 2 | 0.1 | 0.0435 | 0.214 | wilson | |
| Risk difference, group 1 minus group 2 | -0.02 | -0.144 | 0.102 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.8 | 0.228 | 2.81 | log | |
| Odds ratio, group 1 over group 2 | 0.783 | 0.197 | 3.1 | log | |
| Number needed to treat, for one fewer participant with the outcome on 15-methyl Prostaglandin F2α than on Methylergonovine Maleate | 50 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 15-methyl Prostaglandin F2α | IM Carboprost followed by Methylergonovine if needed.~15-methyl prostaglandin F2α: Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine.~Methylergonovine Maleate: Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost. | 4 | 50 | OG000 |
| Group 2 | Methylergonovine Maleate | IM Methylergonovine followed by Carboprost if needed.~15-methyl prostaglandin F2α: Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine.~Methylergonovine Maleate: Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost. | 5 | 50 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Requiring Additional Intervention
- Description
- The need for an additional surgical or radiologic intervention to control postpartum hemorrhage
- Time frame
- within the first 24 hours after delivery of the fetus
- Population
Source ClinicalTrials.gov
Trial
- Title
- Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial
- NCT number
- NCT03584854
- Phases
- PHASE4
- Conditions
- Postpartum Hemorrhage, Uterine Atony
- Interventions
- 15-methyl prostaglandin F2α, Methylergonovine Maleate
- Lead sponsor
- Brigham and Women's Hospital
- Results first posted
- 2025-10-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03584854?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03584854-0beaed03